| Merck (Schweiz) AG - Ogsiveo 150 mg, Filmtabletten | | 70389 | | 02 | | Ogsiveo 150 mg | | Filmtabletten | | L01XX81 | | Nirogacestat | | 19.05.2026 | | |
| | Composition | | nirogacestatum 150 mg ut nirogacestatum dihydrobromidum 199.574 mg, cellulosum microcristallinum, lactosum monohydricum 173.475 mg, natrium max. 1.6 mg, magnesii stearas, Überzug: copolymerum macrogolo et alcoholi poly(vinylico) constatum, talcum, E 171, glyceroli mono/dicaprylocapras, poly(alcohol vinylicus), E 110 0.135 mg, E 172 (flavum), pro compresso obducto. | | Packungsbestandteile | | Comprimés filmés | | | | Principe actif | Concentr. |
|---|
| Nirogacestatum | 150 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Flavum) | | | | Cellulosum Microcristallinum | | | | Copolymerum Macrogolo et Alcoholi Poly(Vinylico) Constatum | | Überzug | | E 110 | 0.135 mg | color. | | E 171 | | color. | | E 172 | | color. | | Glyceroli Mono/dicaprylocapras | | | | Lactose Monohydrate | 173.475 mg | | | Magnesii Stearas | | | | Sodium | 1.6 mg | | | Poly(Alcohol Vinylicus) | | | | Pro Compresso Obducto | | | | Talcum | | |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 002 | 56 | | | A | | Non |
|
|
